Efficacy and Safety of Dapagliflozin and Dapagliflozin plus Saxagliptin in Combination with Metformin in Type 2 Diabetes Patients compared with Sulphonylurea

Trial Identifier: D1689C00014
Sponsor: AstraZeneca
NCTID:: NCT02471404
Start Date: September 2015
Primary Completion Date: March 2017
Study Completion Date: March 2017
Condition: Heart, Blood & Circulatory - Other; Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations